(Q41056531)

English

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the com

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the com (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1 reference

based on heuristic

inferred from title

author name string

Balzarini J

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Pelemans H

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Riess G

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Roesner M

4

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Winkler I

5

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

De Clercq E

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Kleim JP

7

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

language of work or name

0 references

publication date

1 March 1998

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Biochemical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

617-625

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

HIV resistance to reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2', 5'-bis-O-(tert-butyldimethylsilyl)-.beta.-D-xylo- and -ribofuranose]-3'-spiro-5''-[4''-amino-1'', 2''-oxathiole 2''

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900506-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-2952(97)00506-6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41056531&oldid=1584968605"